SIIC MEDTECH<08018> - Results Announcement (Q3, 2002, Summary)
SIIC Medical Science and Technology (Group) Limited announced on 07/11/2002:
(stock code: 08018)
Year end date :31/12/2002
Currency :HKD
Auditors' report :N/A
Review of 3rd Quarterly Report by :Audit Committee
Important Note :
This result announcement form only contains extracted information from
and should be read in conjunction with the detailed results announcement
of the issuer, which can be viewed on the GEM website at
http://www.hkgem.com
(Unaudited) (Unaudited)
Current Last
Corresponding
Period Period
from 01/01/2002 from 01/01/2001
to 30/09/2002 to 30/09/2001
$'000 $'000
Turnover : 643,482 546,003
Profit/(Loss) from Operations : 144,348 135,158
Finance cost : (9) 0
Share of Profit/(Loss) of Associates : 24,118 17,933
Share of Profit/(Loss) of Jointly
Controlled Entites : (406) (117)
Profit/(Loss) after Taxation & MI : 71,667 222,565
% Change Over the Last Period : -67.80 %
EPS / (LPS)
Basic (in dollar) : HKD 0.1156 HKD 0.359
Diluted (in dollar) : HKD 0.1151 N/A
Extraordinary (ETD) Gain/(Loss) : N/A N/A
Profit (Loss) after ETD Items : 71,667 222,565
3rd Quarterly Dividends per Share : NIL NIL
(specify if with other options) : N/A N/A
B/C Dates for 3rd Quarterly Dividends : N/A
Payable Date : N/A
B/C Dates for (-) General Meeting : N/A
Other Distribution for Current Period : NIL
B/C Dates for Other Distribution : N/A
For and on behalf of
SIIC Medical Science and Technology (Group) Limited
Signature :
Name : Wong Mei Ling, Marina
Title : Company Secretary
Responsibility statement
The directors of the Company (the "Directors") as at the date hereof
hereby collectively and individually accept full responsibility for the
accuracy of the information contained in this results announcement form
(the "Information") and confirm, having made all reasonable inquiries,
that to the best of their knowledge and belief the Information are
accurate and complete in all material respects and not misleading and
that there are no other matters the omission of which would make the
Information herein inaccurate or misleading. The Directors acknowledge
that the Stock Exchange has no responsibility whatsoever with regard
to the Information and undertake to indemnify the Exchange against all
liability incurred and all losses suffered by the Exchange in connection
with or relating to the Information.
Remarks:
1. Basis of preparation
The principal accounting policies adopted in preparing the
unaudited consolidated results of the Group conform with accounting
policies generally accepted in Hong Kong and accounting standards
issued by the Hong Kong Society of Accountants. The consolidated
income statement has been prepared under the historial cost
and investment in securities.
2. Comparative figures
Shanghai Jahwa United Co., Ltd. (上海家化聯合股份有限公司)
Group, was listed on the Shanghai Stock Exchange A Shares Market
on 15th March 2001 and became an associate since then. In
accordance with Hong Kong Statements of Standard Accounting
Practice 10 "Accounting for investments in associates", the
Company should include only published financial information of its
financial information for the six months ended 30th June 2001, and
did not publish its financial information for the three months
ended 30th September 2001. As a result, the income statement of
the Group for the three months and nine months ended 30th September
2001 did not include the sharing of results of Shanghai Jahwa for
the three months ended 30th September 2001.
3. Turnover
Turnover represented the net amounts received and receivable for
goods sold by the Group to outside customers during the period.
4. Profit from Operations
During the period, the profit from operations was princially from
Chia Tai Qingchunbao Pharmaceutical Co., Ltd. (正大青春寶藥業有限公司)
5. Earnings per share
The calculation of the basic and diluted earnings per share is
based on the following data:
Nine months ended 30th September
2002 2001
Earnings:
Net profit for the period and
earnings for the purpose of basic
and diluted earnings per share HK$71,667,000 HK$222,565,000
============= ==============
Number of shares:
Weighted average number of
ordinary shares for the
purpose of basic earnings
per share 620,000,000 620,000,000
Effect of dilutive potential
ordinary shares - share options 2,549,768 -
_____________ ______________
Weighted average number of
ordinary shares for the purpose
of diluted earnings per share 622,549,768 620,000,000
============== ==============
|